Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Woo, Jennifer M P ^a   Lin, Zhuofeng ^a   Navab, Mohamad ^a   Van Dyck, Casey ^a   Trejo Lopez, Yvette ^a   Woo, Krystal M T ^a   Li, Hongyun ^a   Castellani, Lawrence W ^a   Wang, Xuping ^a   Iikuni, Noriko ^a   Rullo, Ornella J ^a   Wu, Hui ^a   La Cava, Antonio ^a   Fogelman, Alan M ^a   Lusis, Aldons J ^a   Tsao, Betty P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MIMETIC PEPTIDE; AUTOANTIBODY; BIOLOGICAL MARKER; CD68 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; L 4F; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PEPTIDE; PHOSPHOLIPID; PRAVASTATIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; CHEMOKINE; CYTOKINE; FAS ANTIGEN; IMMUNOGLOBULIN G; L 4F PEPTIDE; L-4F PEPTIDE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BONE DENSITY; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; FEMALE; GLOMERULONEPHRITIS; LUPUS LIKE SYNDROME; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NONHUMAN; OSTEOPENIA; PHENOTYPE; TREATMENT DURATION; VERTEBRA; ANIMAL; ATHEROSCLEROTIC PLAQUE; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, CD95; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BONE DENSITY; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; PLAQUE, ATHEROSCLEROTIC; PRAVASTATIN;

EID: 77952281742     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3020     Document Type: Article

References (57)

1. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism 2001, 44:2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I, 11665973.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
3. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008, 4:605-614. 2515420, 18827910.
4. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406. 10.1056/NEJMoa035471, 14681505.
5. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415. 10.1056/NEJMoa035611, 14681506.
6. Von Feldt JM. The cardiovascular threat of lupus. Nat Clin Pract Rheumatol 2008, 4:505. 10.1038/ncprheum0910, 18820701.
7. Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, Sato K, Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, Sato K. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004, 199:1121-1131. 10.1084/jem.20031557, 2211887, 15096538.
8. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003, 349:2379-2380. 10.1056/NEJMp038168, 14681501.
9. Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanisms. Autoimmun Rev 2006, 5:101-105. 10.1016/j.autrev.2005.08.008, 16431336.
10. Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Chadha AB, Ramsey-Goldman R. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 2006, 45:53-60. 10.1093/rheumatology/kei079, 16278288.
11. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD. Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 2004, 13:436-441. 10.1191/0961203303lu1036oa, 15303570.
12. Ma Z, Choudhury A, Kang SA, Monestier M, Cohen PL, Eisenberg RA. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clinical Immunology 2008, 127:168-175. 10.1016/j.clim.2008.01.002, 2464279, 18325838.
13. Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland EK, Olsen NJ, Major AS. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci USA 2006, 103:7018-7023. 10.1073/pnas.0602311103, 1459011, 16636270.
14. Tamminen M, Mottino G, Qiao JH, Breslow JL, Frank JS. Ultrastructure of Early Lipid Accumulation in ApoE-Deficient Mice. Arterioscler Thromb Vasc Biol 1999, 19:847-853.
15. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985, 37:269-390. full_text, 3890479.
16. Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ, Tsao BP. ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res 2007, 48:794-805. 10.1194/jlr.M600512-JLR200, 17259598.
17. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402. 10.1038/82219, 11100127.
18. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD. Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering. Arterioscler Thromb Vasc Biol 2001, 21:115-121.
19. Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006, 177:3028-3034. 2752011, 16920939.
20. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, George S, Jackson C. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005, 111:1422-1430. 10.1161/01.CIR.0000158435.98035.8D, 15781753.
21. Zhou XX, Gao PJ, Sun BG. Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein e-knockout mice. Clin Exp Pharmacol Physiol 2009, 36:373-379. 10.1111/j.1440-1681.2008.05067.x, 19018808.
22. Shaposhnik Z, Wang X, Weinstein M, Bennett BJ, Lusis AJ. Granulocyte Macrophage Colony-Stimulating Factor Regulates Dendritic Cell Content of Atherosclerotic Lesions. Arterioscler Thromb Vasc Biol 2007, 27:621-627. 10.1161/01.ATV.0000254673.55431.e6, 17158354.
23. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1426-1432. 10.1161/01.ATV.0000167412.98221.1a, 15845909.
24. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234-1241. 10.1172/JCI114558, 296557, 2318976.
25. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001, 21:481-488.
26. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994, 91:9607-9611. 10.1073/pnas.91.20.9607, 44862, 7937814.
27. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM. Apolipoprotein A-I Mimetic Peptides. Arterioscler Thromb Vasc Biol 2005, 25:1325-1331. 10.1161/01.ATV.0000172634.93210.5c, 15831812.
28. Navab M, Hama S, Hough G, Fogelman AM. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 2003, 108:1735-1739. 10.1161/01.CIR.0000089375.60050.35, 14504179.
29. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004, 109:3215-3220. 10.1161/01.CIR.0000134275.90823.87, 15197147.
30. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42:1096-1104.
31. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292. 10.1161/hc0302.103711, 11804981.
32. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol 2000, 20:335-342.
33. Shi W, Wang X, Wang NJ, McBride WH, Lusis AJ. Effect of macrophage-derived apolipoprotein E on established atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000, 20:2261-2266.
34. Gerdes LU, Gerdes C, Klausen IC, Faergeman O. Generation of analytic plasma lipoprotein profiles using two prepacked superose 6B columns. Clin Chim Acta 1992, 205:1-9. 10.1016/0009-8981(92)90348-T, 1521329.
35. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK. Differential effects of apolipoprotein a-i-mimetic peptide on evolving and established atherosclerosis in apolipoprotein e-null mice. Circulation 2004, 110:1701-1705. 10.1161/01.CIR.0000142857.79401.69, 15353488.
36. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Taskén K, Frøland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 2007, 27:614-620. 10.1161/01.ATV.0000255581.38523.7c, 17170367.
37. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei G-Z, De Faire U, Frostegård J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scandinavian Journal of Rheumatology 2008, 37:352-359. 10.1080/03009740802007514, 18666029.
38. Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, Karlson EW. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007, 27:1071-1077. 10.1007/s00296-007-0341-6, 17404733.
39. Graham K, Lee L, Higgins J, Steinman L, Utz P, Ho P. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis and Rheumatism 2008, 58:2098-2104. 10.1002/art.23605, 18576356.
40. Kotyla PJ. Pravastatin, a 3-hydroxy-3-methyl-glutharyl coenzyme A inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus. Rheumatol Int 2009, 29:353-354. 10.1007/s00296-008-0683-8, 18726102.
41. Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007, 46:1560-1565. 10.1093/rheumatology/kem186, 17693444.
42. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci 2008, 82:708-717. 10.1016/j.lfs.2008.01.006, 18289605.
43. Greenspan MD, Yudkovitz JB, Alberts AW, Argenbright LS, Arison BH, Smith JL. Metabolism of lovastatin by rat and human liver microsomes in vitro. Drug Metab Dispos 1988, 16:678-682.
44. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980, 66:1094-1100. 10.1172/JCI109938, 371547, 6903572.
45. Hahn BH, McMahon M. Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies. Lupus 2008, 17:368-370. 10.1177/0961203308089989, 18490409.
46. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis and Rheumatism 2009, 60:2428-2437. 10.1002/art.24677, 19644959, 2753974.
47. Yao GH, Liu ZH, Zhang X, Zheng CX, Chen HP, Zeng CH, Li LS. Circulating thrombomodulin and vascular cell adhesion molecule-1 and renal vascular lesion in patients with lupus nephritis. Lupus 2008, 17:720-726. 10.1177/0961203308089441, 18625649.
48. Okamatsu Y, Kim D, Battaglino R, Sasaki H, Spate U, Stashenko P. MIP-1{gamma} promotes receptor activator of NF-{kappa}B ligand-induced osteoclast formation and survival. J Immunol 2004, 173:2084-2090.
49. Graham LS, Parhami F, Tintut Y, Kitchen CM, Demer LL, Effros RB. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin Immunol 2009, 133:265-275. 10.1016/j.clim.2009.07.011, 19699688.
50. Navab M, Hama SY, Reddy ST, Ng CJ, Van Lenten BJ, Laks H, Fogelman AM. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002, 13:363-372. 10.1097/00041433-200208000-00003, 12151851.
51. Libby P, Geng YJ, Sukhova GK, Simon DI, Lee RT. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci 1997, 811:134-142. 10.1111/j.1749-6632.1997.tb51996.x, 9186592.
52. Nadkarni SK, Pierce MC, Park BH, de Boer JF, Whittaker P, Bouma BE, Bressner JE, Halpern E, Houser SL, Tearney GJ. Measurement of collagen and smooth muscle cell content in atherosclerotic plaques using polarization-sensitive optical coherence tomography. J Am Coll Cardiol 2007, 49:1474-1481. 10.1016/j.jacc.2006.11.040, 2785549, 17397678.
53. Navab M, Ruchala P, Waring AJ, Lehrer RI, Hama S, Hough G, Palgunachari MN, Anantharamaiah GM, Fogelman AM. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res 2009, 50:1538-1547. 10.1194/jlr.M800539-JLR200, 19225094, 2724044.
54. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci 2008, 82:708-717. 10.1016/j.lfs.2008.01.006, 18289605.
55. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007, 27:461-466. 10.1007/s10875-007-9104-0, 17587156.
56. Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T, Shintani A, Stein CM. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. j Rheumatol 2008, 35:1789-1794. 2574747, 18634156.
57. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60:3098-3107. 10.1002/art.24803, 2842939, 19790071.